Tradinity's own scoring, not a copy of any third party's -- see the Key Metrics section for the real ratios behind each number.
Tradinity's own yes/no questions with the rule stated beside each. “Items without enough data are left out, never counted as a No, and the totals count only answered questions. A summary of numbers on this page, not advice.
PE/EPS use each quarter's real filed EPS only from 45 days after quarter-end (no look-ahead) against the raw close of the day. Price-to-book isn't a mode here: the feed has no dated share count, so there's no real history to chart.
Prices adjusted for splits and bonuses. * = a corporate action affecting this date could not be parsed and is not reflected.
Week = 5 sessions, Month = 22 sessions ending the latest trading day — the same combined NSE+BSE delivery data as the table below, just summed.
Data unavailable (needs at least 2 historical quarters with both a filed EPS and a matching trading day).
Data unavailable.
| Date | Client | Deal | Action | Quantity | Price | Exchange |
|---|---|---|---|---|---|---|
| 19 May 2011 | IFCI VENTURE CAPITAL FUND LTD | Bulk | Sell | 123,000 | 42.2700 | BSE |
| 29 Sep 2010 | RAJU BHANDARI | Bulk | Buy | 116,826 | 130.3200 | BSE |
| 18 Aug 2010 | PRIVATBANK IHAG ZURICH AG | Bulk | Buy | 101,087 | 122.9700 | BSE |
| 17 Aug 2010 | RKSV SECURITIES INDIA PRIVATE LIMITED | Bulk | Buy | 109,677 | 120.6200 | BSE |
| 17 Aug 2010 | RKSV SECURITIES INDIA PRIVATE LIMITED | Bulk | Sell | 109,677 | 120.4400 | BSE |
| 17 Aug 2010 | APNA GHAR HSG DEVELOPMENT FINANCE LIMITED | Bulk | Sell | 147,811 | 117.8800 | BSE |
| 16 Aug 2010 | KARVY FINANCIAL SERVICES LIMITED | Bulk | Sell | 228,600 | 113.6400 | BSE |
| 16 Aug 2010 | PRIVATBANK IHAG ZURICH AG | Bulk | Buy | 256,892 | 114.8300 | BSE |
| 13 Aug 2010 | MERRILL LYNCH CAPITAL MARKETS ESPANA SA SV | Bulk | Sell | 92,000 | 142.1200 | BSE |
| 29 Oct 2008 | GOLDMAN SACHS INVESTMENTS MAURITIUS I LTD | Bulk | Sell | 150,843 | 128.0000 | BSE |
| Ex-date | Subject | Per share (₹) | Record date |
|---|---|---|---|
| 21 Sep 2010 | Annual General Meeting And Dividend Rs.2.25 Per Share | 2.2500 | — |
| 19 Sep 2008 | Agm/Dividend - 22.5% | — | — |
| 19 Dec 2007 | Agm/Dividend - 20% Bc Start Date Revised | — | — |
Bonuses, splits, buybacks and other events. Dividends are listed separately above.
| Ex-date | Type | Subject |
|---|---|---|
| — | NAME_CHANGE | Name changed from Mridol Pharmaceuticals Ltd. to Ankur Drugs & Pharma Ltd |
| 20 Dec 2012 | OTHER | Annual General Meeting |
| 21 Sep 2011 | OTHER | Annual General Meeting |
| 23 Sep 2009 | AGM | Agm/Div-Rs.2.25 Per Share |
Exchange disclosures (NSE and BSE), most recent first.
| Date | Category | Announcement |
|---|---|---|
| 24 Apr 2017 | Delisting | Members of the Exchange are hereby notified that in terms of Regulation 22(6) of the Securities and Exchange Board of India (Delisting of Equity Shares) Regulations, 2009 (Regulations), Section 21A of the Securities Contract (Regulations) Act, 1956, Securities Contract Regulations Rules, 1957 and Bye Laws and Regulations of National Stock Exchange of India Limited (Exchange) it has been decided to delist (withdraw the admission to dealings in) equity shares of the Ankur Drugs And Pharma Limited w.e.f. May 12, 2017 as per SEBI (Delisting of Equity Shares) Regulations, 2009. |
| 7 Dec 2016 | Public Notice - Compulsory Delisting | Members of the Exchange are hereby informed that the Exchange on December 04, 2016 has issued public notice in the newspaper for compulsory delisting of equity shares of the company, in term of Regulation 22 (3) of SEBI (Delisting of Equity shares) Regulation, 2009. A copy of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/common/CorporateAnnouncements). |
| 6 Sep 2013 | Suspension of trading in equity shares | Members of the Exchange are hereby informed that trading in the equity shares of Ankur Drugs And Pharma Limited will be suspended w.e.f. September 11, 2013 (i.e. closing hours of trading on September 10, 2013) as the company has failed to respond to the notices of the Exchange for non-compliance with the provisions of listing agreement. It may also be noted that the Official Liquidator of Hon'ble High Court of Bombay, has informed the Exchange that, by an order dated 08-07-2013 passed by Hon'ble High Court of Bombay in C P No: 103 of 2012, Ankur Drugs And Pharma Limited shall be wound up and the Official Liquidator has been directed to take possession. |
| 2 Sep 2013 | Updates | Ministry of Corporate Affairs has informed the Exchange regarding an order dated 8/7/2013 passed by the Hon'ble Court in Company Petition No. 103 of 2012 in the matter of Ankur Drugs and Pharma Ltd. |
| 1 Jul 2013 | Resignation of Director | Ankur Drugs And Pharma Limited has informed the Exchange that the Board of Directors of the company at its meeting held on June 29, 2013 has taken the following decision: 1) Resignation of Mr. Anil Kumar Khadke as Nominee Director of Central Bank of India w.e.f March 15, 2013 has been accepted by the Board. |
| 26 Jun 2013 | Price movement | Price movement : Significant price movement has been observed in Ankur Drugs And Pharma Limited. The Exchange, in order to ensure that investors have latest relevant information about the company and to inform the market place so that the interest of the investors is safeguarded, had written to the company. Ankur Drugs And Pharma Limited has vide its letter inter-alia stated, "In this connection we have to advice that no activity influencing the price movement of scrip is taking place in the Company. The volatility in the movement of the scrip price is purely market driven and Company in nowhere involved in the same." |
| 22 May 2013 | Updates | Ankur Drugs And Pharma Limited has informed the Exchange that"FCCB holders had filed a petition challanging the scheme of arrangement proposed by the Company before the Hon'ble High Court of the judicature of Bombay. The Hon'ble High Court of the judicature of Bombay vide their order dated May 21, 2013 has stayed the holding of the meeting of Equity Shareholders, Secured Creditors, Unsecured and other Creditors, FCCB holders and Depositors of Ankur Drugs and Pharma Ltd scheduled for Wednesday the 22nd May, 2013 and Friday the 24th May, 2013, respectively till further orders." |
| 15 May 2013 | Court Convened Meeting Updates | Ankur Drugs And Pharma Limited has submitted to the Exchange a copy of the Notices for holding meetings of Equity Shareholders, Secured Creditors, Unsecured Creditors, Other Creditors, FCCB Holders and Depositors of the Company to be held on May 22, 2013. |
| 18 Apr 2013 | Updates | Ankur Drugs And Pharma Limited has informed the Exchange that the Company had received Order from Hon'ble High Court dated March 15, 2013, directing the Company to hold Meeting of Equity Shareholders and Secured Creditors on April 20, 2013 and Meeting of Unsecured and other Creditors, FCCB Holders and Depositors on April 22, 2013 in respect of Scheme of Arrangement and Compromise filed by the Company. Further, the Company had filed an application to Hon'ble Court Bombay for extending time period for holding meeting of Shareholders and Creditors and in this respect, Hon'ble High Court, Bombay have accepted application of the Company and have directed the Company to hold Meeting Equity Shareholders and Secured Creditors on May 22, 2013 and Meeting of Unsecured and other Creditors, FCCB Holders and Depositors on May 24, 2013. |
| 16 Apr 2013 | Updates | Ankur Drugs And Pharma Limited has informed the Exchange vide letter dated April 15, 2013 that the Company had received Order from Hon'ble High Court dated March 15, 2013 in respect of Scheme of Arrangement and Compromise filed by the Company. In the said Order Hon'ble High Court have directed the Company to Convene Meeting of Creditors and Shareholders to take approval on Scheme of Arrangement and Compromise as proposed by the Company. The Company is in process of making arrangement to convene meeting of creditors and shareholders. |
Tradinity's own rule-based read of the real ratios elsewhere on this page -- not a copy of any third party's, and never a forward-looking prediction.
Data unavailable.
Data unavailable.
Data unavailable.
Board of directors and corporate information →
Data unavailable (no single-stock futures or options activity on record for this company).
The price at the top of this page is the last traded price from exchange data; during market hours it refreshes on its own. The Chart & Technicals section has the full price history.
The Financials page has quarterly and annual results, ratios, cash flow and the balance sheet, on a standalone or consolidated basis.
The Ownership section shows the latest shareholding pattern from exchange filings, with promoter, FII, DII and public holdings by quarter.
No. The scores and checklist on this page are rule-based summaries of published figures, not recommendations. Tradinity is not a registered investment adviser.
